|
. |
24 1/2 |
|
|
Subject |
Hyundai Pharm, MIRAP ER Tab, Parkinson¡¯s disease drug, launch |
Content |
Hyundai Pharm, MIRAP ER Tab, Parkinson¡¯s disease drug, launch
Hyundai, Expects Synergistic effect through CNS products reinforcement
Hyundai Pharm (President, Yeong Hak Kim) stated Hyundai will launch Parkinson disease drug Mirap ER (Pramipexole, Original: Mirapex)
Mirap ER (Pramipexole), Parkinsons disease treatment, is used as monotherapy for the early treatment and also combination treatment with levodopa is also possible for ongoing Parkinson¡¯s disease patients. Its administration is much convenient now where it is taken once a day compare to three times day of traditional regimen.
Mirap ER is a non-ergot dopamine agonist and the first new generic as a sustained release form of pramipexole in Korea. It improves the Parkinson¡¯s symptoms such as dyskinesia symptoms by binding to dopamine receptors in the striatum increasing dopamine activity. |
Date |
2014-03-28 |
|
|
|
|
|